Satellos Bioscience Inc. Share Price
Stocks
MSCL
CA80401L8033
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Toronto S.E.
11:57:56 19/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 9.150 CAD | -1.08% |
|
-7.58% | +15.53% |
| 05/10 | Satellos Bioscience Granted Composition of Matter Patent for Forazapadin by USPTO | MT |
| 05/10 | Satellos Bioscience Receives US Patent for Forazapadin | MT |
| Market Cap | 14Cr 12Cr 11Cr 10Cr 20Cr 1.32TCr 20Cr 137.41Cr 54Cr 687.5Cr 52Cr 51Cr 2.2TCr | P/E 2026 * |
-3.14x | P/E 2027 * | -4.15x |
|---|---|---|---|---|---|
| Enterprise Value | 3.71Cr 3.31Cr 3.07Cr 2.79Cr 5.23Cr 352.13Cr 5.32Cr 37Cr 14Cr 184.04Cr 14Cr 14Cr 588.34Cr | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
93.63% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Toronto S.E.
| MSCL | Delayed | |
Nasdaq
| MSLE | Delayed | |
|
CBOE
| MSLE | Real-time | |
|
Deutsche Boerse AG
| 0IT | Delayed | |
|
Tradegate
| 0IT | Real-time | |
|
Börse Stuttgart
| 0IT | Delayed |
| 1 day | -1.08% | ||
| 1 week | -7.58% | ||
| Current month | -24.32% | ||
| 1 month | -28.90% | ||
| 3 months | -21.93% | ||
| 6 months | -14.49% | ||
| Current year | +15.53% |
| 1 week | 9.15 |  | 10.7 |
| 1 month | 9.15 | | 13.1 |
| Current year | 7.67 | | 18.98 |
| 1 year | 7.56 | | 18.98 |
| 3 years | 3.48 | | 18.98 |
| 5 years | 2.58 | | 19.08 |
| 10 years | 2.58 | | 22.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Gleeson
CEO | Chief Executive Officer | 70 | 01/03/2018 |
Michael Rudnicki
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2018 |
| Director of Finance/CFO | - | 01/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Geoff MacKay
CHM | Chairman | 59 | 01/07/2018 |
Brian Bloom
BRD | Director/Board Member | 50 | 01/03/2018 |
Frank Gleeson
BRD | Director/Board Member | 70 | 01/07/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 18/08/26 | Option | Director | 10,608 | 0.0509% | ||
| 18/08/26 | Option | Director | 10,608 | 0.0509% | ||
| 18/08/26 | Option | Director | 10,608 | 0.0509% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.08% | -7.58% | -3.48% | +90.62% | 14Cr | |
| +1.52% | -7.16% | +51.66% | +67.41% | 6.5TCr | |
| +1.52% | +6.83% | +10.89% | +79.30% | 5.12TCr | |
| +0.30% | -0.46% | -0.03% | +61.89% | 5.12TCr | |
| -0.77% | +0.96% | +24.84% | +41.75% | 4.39TCr | |
| +0.84% | +6.02% | +16.60% | +134.12% | 4.2TCr | |
| +2.44% | -5.96% | +237.71% | +528.95% | 3.81TCr | |
| +2.16% | +10.36% | +18.92% | +59.70% | 3.32TCr | |
| -0.90% | -10.49% | +37.09% | +1.80% | 2.52TCr | |
| +1.60% | +2.21% | +27.96% | +28.00% | 2.25TCr | |
| Average | +0.74% | -1.24% | +42.22% | +109.35% | 3.73TCr | |
| Weighted average by Cap. | +0.96% | +0.03% | +45.53% | +112.53% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -4.99Cr -4.45Cr -4.12Cr -3.75Cr -7.03Cr -473.28Cr -7.15Cr -49Cr -19Cr -247.36Cr -19Cr -18Cr -790.76Cr | -6.55Cr -5.84Cr -5.41Cr -4.92Cr -9.23Cr -621.05Cr -9.38Cr -65Cr -26Cr -324.6Cr -25Cr -24Cr -1.04TCr |
| Net Debt | -10Cr -9.06Cr -8.39Cr -7.63Cr -14Cr -963.27Cr -15Cr -100.63Cr -40Cr -503.46Cr -38Cr -37Cr -1.61TCr | -12Cr -11Cr -9.83Cr -8.93Cr -17Cr -1.13TCr -17Cr -117.86Cr -46Cr -589.68Cr -45Cr -44Cr -1.89TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/26/19 | CA$9.150 | -1.08% | 4,746 |
| 16/26/16 | CA$9.250 | -5.52% | 13,239 |
| 15/26/15 | CA$9.790 | +3.05% | 3,963 |
| 14/26/14 | CA$9.500 | -4.04% | 6,087 |
| 13/26/13 | CA$9.900 | -7.56% | 37,667 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MSCL Stock
Select your edition
All financial news and data tailored to specific country editions
